

9 October 2026

To

BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Intimation regarding receipt of Central Government approval for appointment of Mr. Umang Vohra as Chairman and Group CEO of the Company

In continuation of our letters dated 27 April 2026 and 26 June 2026 regarding appointment of Mr. Umang Vohra (DIN: 02296740) as Chairman and Group CEO of the Company, we wish to inform you that the Ministry of Corporate Affairs (Central Government) vide its letter dated 8 October 2026 (received by the Company on 12 October 2026) has approved the said appointment.

This is for your information and records.

Thanking you

Yours faithfully,

For **Cohance Lifesciences Limited**

(formerly, Suven Pharmaceuticals Limited)

Sisira

Kumar

Mishra

Sisir K. Mishra

Company Secretary & Compliance Officer

Digitally signed by
Sisira Kumar Mishra
Date: 2026.10.12
19:47:22 +05'30'

Cohance Lifesciences Limited

(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

